How to Optimize Your GLP-1 Investments
A guide to developing sustainable GLP-1 strategies
GLP-1s for weight loss and diabetes stand to benefit a significant portion of the population. But runaway costs are not sustainable, especially if weight loss and/or blood sugar control are not achieved or sustained after deprescription. Plan sponsors must find ways to balance access, utilization and member satisfaction while optimizing the impact of these medications.
This new whitepaper provides valuable insights for leaders looking to optimize the impact of GLP-1 investments, including:
- Why not covering these medications does not equal no cost
- What traditional and new utilization management strategies organizations are using to control access and manage costs related to GLP-1s
- How to avoid wasted spend and deliver outcomes, including metrics to monitor the impact of your GLP-1 strategies
How to Optimize Your GLP-1 Investments
A guide to developing sustainable GLP-1 strategies
GLP-1s for weight loss and diabetes stand to benefit a significant portion of the population. But runaway costs are not sustainable, especially if weight loss and/or blood sugar control are not achieved or sustained after deprescription. Plan sponsors must find ways to balance access, utilization and member satisfaction while optimizing the impact of these medications.
This new whitepaper provides valuable insights for leaders looking to optimize the impact of GLP-1 investments, including:
- Why not covering these medications does not equal no cost
- What traditional and new utilization management strategies organizations are using to control access and manage costs related to GLP-1s
- How to avoid wasted spend and deliver outcomes, including metrics to monitor the impact of your GLP-1 strategies